nach oben

Die Kardiologie

Erschienen in:

21.01.2019 | TAVI | CME

Kathetergestützte Aortenklappenimplantation (TAVI)

verfasst von: Dr. M. Weber, Prof. Dr. N. Werner

Erschienen in: Die Kardiologie | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Heutzutage stellt der kathetergestützte Aortenklappenersatz (TAVI) ein Standardverfahren zur Therapie der symptomatischen, hochgradigen Aortenklappenstenose dar. Während TAVI zunächst nur bei Hochrisikopatienten ohne operativen Therapieansatz eingesetzt wurde, zeigen aktuelle Studien bei Patienten mit mittlerem operativem Risiko vergleichbare Überlebensraten nach TAVI und operativem Aortenklappenersatz. Beide Therapieansätze unterscheiden sich jedoch bezüglich der Art und Häufigkeit von Komplikationen. In diesem Übersichtsbeitrag fassen die Autoren die aktuellsten randomisierten Studien zusammen, die TAVI mit dem operativen Aortenklappenersatz vergleichen, und geben einen Überblick über zukünftige Entwicklungen.

Otto CM, Lind BK, Kitzman DW et al (1999) Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 341:142–147CrossRef

Soler-Soler J, Galve E (2000) Worldwide perspective of valve disease. Heart 83:721–725CrossRef

Iung B, Baron G, Butchart EG et al (2003) A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 24:1231–1243CrossRef

Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 38:2739–2791CrossRef

Baumgartner HC, Hung JC-C, Bermejo J et al (2017) Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 18:254–275CrossRef

Lababidi Z (1983) Aortic balloon valvuloplasty. Am Heart J 106:751–752CrossRef

Cribier A, Eltchaninoff H, Bash A et al (2002) Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 106:3006–3008CrossRef

Reinohl J, Kaier K, Reinecke H et al (2015) Effect of availability of transcatheter aortic-valve replacement on clinical practice. N Engl J Med 373:2438–2447CrossRef

Rodes-Cabau J, Webb JG, Cheung A et al (2010) Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 55:1080–1090CrossRef

10.

Tamburino C, Capodanno D, Ramondo A et al (2011) Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 123:299–308CrossRef

11.

Thomas M, Schymik G, Walther T et al (2010) Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 122:62–69CrossRef

12.

Piazza N, Grube E, Gerckens U et al (2008) Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1‑year following CE mark approval. EuroIntervention 4:242–249CrossRef

13.

Leon MB, Smith CR, Mack M et al (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363:1597–1607CrossRef

14.

Smith CR, Leon MB, Mack MJ et al (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364:2187–2198CrossRef

15.

Reardon MJ, Van Mieghem NM, Popma JJ et al (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376:1321–1331CrossRef

16.

Leon MB, Smith CR, Mack MJ et al (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374:1609–1620CrossRef

17.

Kodali SK, Williams MR, Smith CR et al (2012) Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 366:1686–1695CrossRef

18.

Kapadia SR, Leon MB, Makkar RR et al (2015) 5‑year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385:2485–2491CrossRef

19.

Mack MJ, Leon MB, Smith CR et al (2015) 5‑year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385:2477–2484CrossRef

20.

Grube E, Laborde JC, Gerckens U et al (2006) Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation 114:1616–1624CrossRef

21.

Adams DH, Popma JJ, Reardon MJ et al (2014) Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370:1790–1798CrossRef

22.

Reardon MJ, Adams DH, Kleiman NS et al (2015) 2‑year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. J Am Coll Cardiol 66:113–121CrossRef

23.

Thourani VH, Kodali S, Makkar RR et al (2016) Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet 387:2218–2225CrossRef

24.

Thyregod HG, Steinbruchel DA, Ihlemann N et al (2015) Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1‑year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol 65:2184–2194CrossRef

25.

Sondergaard L, Steinbruchel DA, Ihlemann N et al (2016) Two-year outcomes in patients with severe aortic valve stenosis randomized to transcatheter versus surgical aortic valve replacement: the all-comers nordic aortic valve intervention randomized clinical trial. Circ Cardiovasc Interv. https://doi.org/10.1161/circinterventions.115.003665 CrossRefPubMed

26.

Bosmans J, Bleiziffer S, Gerckens U et al (2015) The incidence and predictors of early- and mid-term clinically relevant neurological events after transcatheter aortic valve replacement in real-world patients. J Am Coll Cardiol 66:209–217CrossRef

27.

Hamm CW, Arsalan M, Mack MJ (2016) The future of transcatheter aortic valve implantation. Eur Heart J 37:803–810CrossRef

28.

Gaede L, Blumenstein J, Liebetrau C et al (2018) Outcome after transvascular transcatheter aortic valve implantation in 2016. Eur Heart J 39:667–675CrossRef

29.

Kapadia SR, Kodali S, Makkar R et al (2017) Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol 69:367–377CrossRef

30.

Haussig S, Mangner N, Dwyer MG et al (2016) Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial. JAMA 316:592–601CrossRef

31.

Van Mieghem NM, Van Gils L, Ahmad H et al (2016) Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial. EuroIntervention 12:499–507CrossRef

32.

Lansky AJ, Schofer J, Tchetche D et al (2015) A prospective randomized evaluation of the TriGuard HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J 36:2070–2078CrossRef

33.

Seeger J, Gonska B, Otto M et al (2017) Cerebral embolic protection during transcatheter aortic valve replacement significantly reduces death and stroke compared with unprotected procedures. JACC Cardiovasc Interv 10:2297–2303CrossRef

34.

Abdul-Jawad Altisent O, Durand E, Munoz-Garcia AJ et al (2016) Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 9:1706–1717CrossRef

35.

Sondergaard L, Sawaya FJ (2017) Antithrombotic management after transcatheter aortic valve replacement: more questions than answers. JACC Cardiovasc Interv 10:75–78CrossRef

36.

Nazif TM, Dizon JM, Hahn RT et al (2015) Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv 8:60–69CrossRef

37.

Urena M, Mok M, Serra V et al (2012) Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol 60:1743–1752CrossRef

38.

Urena M, Hayek S, Cheema AN et al (2015) Arrhythmia burden in elderly patients with severe aortic stenosis as determined by continuous electrocardiographic recording: toward a better understanding of arrhythmic events after transcatheter aortic valve replacement. Circulation 131:469–477CrossRef

39.

Weber M, Bruggemann E, Schueler R et al (2015) Impact of left ventricular conduction defect with or without need for permanent right ventricular pacing on functional and clinical recovery after TAVR. Clin Res Cardiol 104:964–974CrossRef

40.

Sondergaard L, De Backer O, Kofoed KF et al (2017) Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves. Eur Heart J 38:2201–2207CrossRef

41.

Makkar RR, Fontana G, Jilaihawi H et al (2015) Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 373:2015–2024CrossRef

42.

Pasic M, Unbehaun A, Buz S et al (2015) Annular rupture during transcatheter aortic valve replacement: classification, pathophysiology, diagnostics, treatment approaches, and prevention. JACC Cardiovasc Interv 8:1–9CrossRef

43.

Ribeiro HB, Webb JG, Makkar RR et al (2013) Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J Am Coll Cardiol 62:1552–1562CrossRef

44.

Roy DA, Schaefer U, Guetta V et al (2013) Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J Am Coll Cardiol 61:1577–1584CrossRef

45.

Wendt D, Kahlert P, Pasa S et al (2014) Transapical transcatheter aortic valve for severe aortic regurgitation: expanding the limits. JACC Cardiovasc Interv 7:1159–1167CrossRef

46.

Azadani AN, Tseng EE (2011) Transcatheter heart valves for failing bioprostheses: state-of-the-art review of valve-in-valve implantation. Circ Cardiovasc Interv 4:621–628CrossRef

47.

Dvir D, Webb J, Brecker S et al (2012) Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. Circulation 126:2335–2344CrossRef

48.

Tarantini G, Purita PAM, D’Onofrio A et al (2017) Long-term outcomes and prosthesis performance after transcatheter aortic valve replacement: results of self-expandable and balloon-expandable transcatheter heart valves. Ann Cardiothorac Surg 6:473–483CrossRef

Titel: Kathetergestützte Aortenklappenimplantation (TAVI)
verfasst von: Dr. M. Weber
Prof. Dr. N. Werner
Publikationsdatum: 21.01.2019
Verlag: Springer Medizin
Schlagwörter: TAVI
Aortenklappenersatz
Apoplex
Aortenklappenersatz
Aortenklappenstenose
Aortenklappeninsuffizienz
Aortenklappenersatz
Erschienen in: Die Kardiologie / Ausgabe 1/2019
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI: https://doi.org/10.1007/s12181-018-0298-6

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Curriculum Sportkardiologie

Vorhofflimmern nach nichtkardialer Operation: Dauerhafte Antikoagulation notwendig?

Leitlinie Arterielle Hypertonie – von Experten kommentiert

Panorama

Psychokardiologische Rehabilitation – interdisziplinäre Behandlung als Pilotprojekt

PFO-Verschluss: Vorhofflimmern meist früh nach dem Eingriff